C07C229/52

NOVEL SUBSTITUTED QUINOLINE AND TETRAHYDRONAPHTHALENE CARBOXYLIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF
20260055080 · 2026-02-26 ·

Disclosed herein is a compound, or a pharmaceutically acceptable salt thereof, in particular hydrochloride salt thereof, characterized in that said compound is selected from the following compounds: -4-(4-((1-(3-fluoropropyl)azetidin-3-yl)oxy)benzoyl)-3-(4-(trifluoromethyl)phenyl)quinoline-7-carboxylic acid (1), -3-(2-fluoro-4-(trifluoromethyl)phenyl)-4-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)benzoyl)quinoline-7-carboxylic acid (2), and -(R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (3). Further disclosed are process for preparing the same, pharmaceutical compositions comprising them as well as said compounds of formula (I) for use as an inhibitor and degrader of estrogen receptors, in particular in the treatment of ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation.

NOVEL SUBSTITUTED QUINOLINE AND TETRAHYDRONAPHTHALENE CARBOXYLIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF
20260055080 · 2026-02-26 ·

Disclosed herein is a compound, or a pharmaceutically acceptable salt thereof, in particular hydrochloride salt thereof, characterized in that said compound is selected from the following compounds: -4-(4-((1-(3-fluoropropyl)azetidin-3-yl)oxy)benzoyl)-3-(4-(trifluoromethyl)phenyl)quinoline-7-carboxylic acid (1), -3-(2-fluoro-4-(trifluoromethyl)phenyl)-4-(4-(2-(3-(fluoromethyl)azetidin-1-yl)ethoxy)benzoyl)quinoline-7-carboxylic acid (2), and -(R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid (3). Further disclosed are process for preparing the same, pharmaceutical compositions comprising them as well as said compounds of formula (I) for use as an inhibitor and degrader of estrogen receptors, in particular in the treatment of ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation.

POLYMERIC (METH)ACRYLATE PHOTOINITIATORS

The present invention relates to novel photoinitiators having improved reactivity and surface curing and/or lower post-cure yellowing and to photopolymerization compositions containing said photoinitiators. The invention also concerns a process for the photopolymerization of compositions comprising said photoinitiators as well as their use in articles of manufacture, including printed, coated, and fabricated assemblies.

POLYMERIC (METH)ACRYLATE PHOTOINITIATORS

The present invention relates to novel photoinitiators having improved reactivity and surface curing and/or lower post-cure yellowing and to photopolymerization compositions containing said photoinitiators. The invention also concerns a process for the photopolymerization of compositions comprising said photoinitiators as well as their use in articles of manufacture, including printed, coated, and fabricated assemblies.